Biogen Q3 results better than expected, updrades guidance
The US-based biotech company Biogen has released its Q3 report for 2021, stating that sales and revenue decrease was smaller than expected – subsequently, financial guidance is upgraded.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
The US premarket indicator for Biogen stock is up 1.8 percent at USD 273.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen stumbles in crucial ALS study
For subscribers
Roche soars in Q3, carried by Covid-19 test demand
For subscribers
.jpg&w=384&q=75)
